Business
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. “We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Biopharma’s current phase of corporate development and growth,” said Daniel Passeri, chief executive officer of Cue Biopharma. “Mr. Verheyen’s prolific career in business development, licensing deals and mergers & acquisitions will be extremely valuable as we continue to advance our lead clinical drug candidates, CUE-101 and CUE-102, and identify strategic initiatives to further develop our promising platform technologies and derived drug candidates globally.” Mr. Verheyen added, “I am honored to join Cue Biopharma’s BOD and its talented team of immunologists, biotech leaders and scientists. Cue Biopharma’s platform technology and drug product candidates represent a unique targeted approach to the treatment of cancer and autoimmune diseases. As a new member of the BOD, I look forward to helping guide the Company’s strategic initiatives and further build on the impressive progress the company has made to date with the promise of their platform technologies representing a potential breakthrough approach in immunotherapy for cancer and autoimmune disease.” Mr. Verheyen had a distinguished 35-year career with Janssen Pharmaceutical Companies of Johnson & Johnson where he held positions of growing responsibility until his retirement as Global Head, Janssen Business Development in 2021. During his time there he led Janssen’s Business Development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals across Janssen’s therapeutic areas of focus. Mr. Verheyen led the 2017 $30B acquisition of Actelion, which established Janssen’s footprint in the Pulmonary Hypertension spa...